Category: bispecific antibody

  • AACR: Affimed builds case for natural killer cell therapy

    Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13 provide further evidence of its efficacy in treating CD30+ Hodgkin and non-Hodgkin lymphoma patients, although not for the version that will likely be filed for approval. The MD Anderson study now has data from 19 patients, with […]

  • Sanofi places $75m bet with ABL on popular Parkinson’s drug target

    Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. The French pharma group is paying $75 million upfront for the preclinical-stage drug, codenamed ABL301, a double headed antibody […]

  • J&J bulks up in bispecifics with $1.3bn Xencor alliance

    Fresh from claiming its first bispecific antibody approval, Johnson & Johnson has delved deeper into the category with a deal to license a drug for B-cell cancers developed by Xencor. J&J’s Janssen Biotech unit is paying $100 million upfront to Xencor and making a $25 million equity investment in the biotech in return for rights […]

  • Straight after its first cancer bispecific OK, J&J highlights two more at ASCO

    With the ink barely dry on the FDA’s approval of Johnson & Johnson’s Rybrevant, its first bispecific antibody for cancer, the drugmaker is already showcasing others in its pipeline.  Two of its earlier-stage bispecifics – both in development for the blood cancer multiple myeloma – will feature at the American Society of Clinical Oncology (ASCO) […]

  • Lilly bolts on cancer bispecifics with $1.6bn Merus alliance

    Always a big player in oncology, Eli Lilly has fallen behind some of its rivals when it comes to cancer immunotherapy, but a new R&D alliance with Dutch biotech Merus is further evidence of its fightback. Lilly is tapping into Merus’ expertise in bispecific antibodies, specifically antibodies that target cancer cells with one end of […]